Price (delayed)
$2.2
Market cap
$59.56M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.5
Enterprise value
-$93.1M
We are a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Building on more than a decade of
There are no recent dividends present for ANRO.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.